134 related articles for article (PubMed ID: 24636376)
1. Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
Vataire AL; Aballéa S; Antonanzas F; Roijen LH; Lam RW; McCrone P; Persson U; Toumi M
Value Health; 2014 Mar; 17(2):183-95. PubMed ID: 24636376
[TBL] [Abstract][Full Text] [Related]
2. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
Armstrong EP; Malone DC; Erder MH
Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression.
Nguyen KH; Gordon LG
Value Health; 2015 Jul; 18(5):597-604. PubMed ID: 26297087
[TBL] [Abstract][Full Text] [Related]
4. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
[TBL] [Abstract][Full Text] [Related]
6. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
Leelahanaj T
J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
[TBL] [Abstract][Full Text] [Related]
9. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom.
Wade AG; Toumi I; Hemels ME
Clin Ther; 2005 Apr; 27(4):486-96. PubMed ID: 15922821
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA
J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom.
Young AH; Evitt L; Brignone M; Diamand F; Atsou K; Campbell R; Cure S; Danchenko N
J Affect Disord; 2017 Aug; 218():291-298. PubMed ID: 28478358
[TBL] [Abstract][Full Text] [Related]
12. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.
Fajutrao L; Paulsson B; Liu S; Locklear J
Clin Ther; 2009 Jun; 31 Pt 1():1456-68. PubMed ID: 19698903
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.
Hornberger J; Li Q; Quinn B
Am J Manag Care; 2015 Jun; 21(6):e357-65. PubMed ID: 26247576
[TBL] [Abstract][Full Text] [Related]
18. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain].
Rejas Gutiérrez J; Blanca Tamayo M; Gascón Barrachina J; Armada Peláez B
Rev Psiquiatr Salud Ment; 2016; 9(2):87-96. PubMed ID: 26475204
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clinical guidelines for continuation treatment in major depression.
Nuijten MJ
Value Health; 2001; 4(4):281-94. PubMed ID: 11705296
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.
Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
BMC Health Serv Res; 2013 May; 13():173. PubMed ID: 23663281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
